Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Jul 31;97(5):637–645. doi: 10.1038/sj.bjc.6603918

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest (31.9%) did not express the peptide (C). CRHR1 was expressed in 70.2% of cases (D, E) and absent from 29.8% (F). CRHR2 was expressed in 63.8% (G, H) of cases and absent from 36.2% (I). Finally, 63.8% of the cases were positive for FasL (J, K) and 36.2% were negative (L). Lens × 10 (A, C, D, F, G, I, J, L), × 40 (B, E, H, K). (M) Staining intensity was determined by the semiquantitative immunohistochemical IRS. There was a statistically significant increase in CRH and FasL expression between stage II and stage IV tumours. Data represent mean±s.e. (^*P<0.05).